Laurence Reid, PhD

Dr. Lau­rence Reid is an entre­pre­neur, com­pa­ny builder, and biotech exec­u­tive, lever­ag­ing his expe­ri­ence as an advi­sor to grow­ing biotech com­pa­nies. He cur­rent­ly serves as chair­per­son of the board of direc­tors of Bro­ken String Bio­sciences Ltd. and on the boards of direc­tors of KalVista Phar­ma­ceu­ti­cals, Inc. (NASDAQ: KALV) and sev­er­al oth­er pri­vate biotech­nol­o­gy com­pa­nies. Pre­vi­ous­ly, Dr. Reid was pres­i­dent and CEO of Deci­bel Ther­a­peu­tics, Inc., until its acqui­si­tion by Regen­eron Phar­ma­ceu­ti­cals, Inc. in 2023, and CEO of Warp Dri­ve Bio, LLC until its merg­er with Rev­o­lu­tion Med­i­cines, Inc. in 2018. He has also served as an entre­pre­neur in res­i­dence at Third Rock Ven­tures LLC.

Pri­or to that, Dr. Reid served as Chief Busi­ness Offi­cer of Alny­lam Phar­ma­ceu­ti­cals, Inc., and as Gen­er­al Man­ag­er of Mil­len­ni­um Europe at Mil­len­ni­um Phar­ma­ceu­ti­cals, Inc., which is now part of Take­da Phar­ma­ceu­ti­cal Com­pa­ny Lim­it­ed. He received a BA in Nat­ur­al Sci­ences from Cam­bridge Uni­ver­si­ty and a PhD in bio­chem­istry from King’s Col­lege, Uni­ver­si­ty of London.